Trial | NCT02383927  Report issue

Title

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    zarnestra ...

  • Study Participants

    63
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and cohort 3 (Other SCC) are currently open
This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subjects with information available on tumor HRAS status previously generated are eligible. All subjects must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a retrospective testing of HRAS gene status at a central facility.

Subjects will be enrolled into three nonrandomized cohorts:

Cohort 1: Malignant thyroid tumors with HRAS mutations (cohort is closed).
Cohort 2: Squamous Cell Carcinoma Head and Neck Cancer with HRAS mutations.
Cohort 3: Squamous Cell Carcinoma (SCC) with HRAS mutations other than HNSCC
Study Started
Mar 31
2015
Primary Completion
Nov 30
2020
Study Completion
Nov 30
2020
Last Update
May 14
2021

Drug Tipifarnib

FTase inhibitor

  • Other names: Zarnestra

Cohort 1 Experimental

Thyroid Cancer

Cohort 2 Experimental

Squamous Head and Neck Cancer

Criteria 

Inclusion Criteria:

histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1: Note: Cohort closed to further enrolment) or Squamous Cell Carcinoma head and neck cancer (cohort 2) or Squamous Cell Carcinoma other than HNSCC (cohort 3) for which there is no curative therapy available.
tumor that carries a missense HRAS mutation ith a variant allele frequency (VAF) > 20%.
Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status
Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.
At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
ECOG PS 0 or 1
Acceptable liver function
Acceptable renal function
Acceptable hematologic status • Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥ 35%) may be enrolled despite a serum albumin < 3.5 g/dL.

Exclusion Criteria:

Prior treatment with an FTase inhibitor
History of relevant coronary heart disease or myocardial infarction within last 3 years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or serious cardiac arrhythmia requiring medication except atrial fibrillation.
Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day 1.
Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose
Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C
No Results Posted